Literature DB >> 31395771

Vascular regulation of antitumor immunity.

Lance L Munn1, Rakesh K Jain2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31395771      PMCID： PMC7321824          DOI： 10.1126/science.aaw7875

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


× No keyword cloud information.
  13 in total

1.  Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation.

Authors:  Elizabeth Allen; Arnaud Jabouille; Lee B Rivera; Inge Lodewijckx; Rindert Missiaen; Veronica Steri; Kevin Feyen; Jaime Tawney; Douglas Hanahan; Iacovos P Michael; Gabriele Bergers
Journal:  Sci Transl Med       Date:  2017-04-12       Impact factor: 17.956

Review 2.  Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.

Authors:  Dai Fukumura; Jonas Kloepper; Zohreh Amoozgar; Dan G Duda; Rakesh K Jain
Journal:  Nat Rev Clin Oncol       Date:  2018-03-06       Impact factor: 66.675

3.  Increased vessel perfusion predicts the efficacy of immune checkpoint blockade.

Authors:  Xichen Zheng; Zhaoxu Fang; Xiaomei Liu; Shengming Deng; Pei Zhou; Xuexiang Wang; Chenglin Zhang; Rongping Yin; Haitian Hu; Xiaolan Chen; Yijie Han; Yun Zhao; Steven H Lin; Songbing Qin; Xiaohua Wang; Betty Ys Kim; Penghui Zhou; Wen Jiang; Qingyu Wu; Yuhui Huang
Journal:  J Clin Invest       Date:  2018-04-16       Impact factor: 14.808

4.  Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy.

Authors:  Yuhui Huang; Jianping Yuan; Elda Righi; Walid S Kamoun; Marek Ancukiewicz; Jean Nezivar; Michael Santosuosso; John D Martin; Margaret R Martin; Fabrizio Vianello; Pierre Leblanc; Lance L Munn; Peigen Huang; Dan G Duda; Dai Fukumura; Rakesh K Jain; Mark C Poznansky
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-08       Impact factor: 11.205

5.  Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival.

Authors:  Jonas Kloepper; Lars Riedemann; Zohreh Amoozgar; Giorgio Seano; Katharina Susek; Veronica Yu; Nisha Dalvie; Robin L Amelung; Meenal Datta; Jonathan W Song; Vasileios Askoxylakis; Jennie W Taylor; Christine Lu-Emerson; Ana Batista; Nathaniel D Kirkpatrick; Keehoon Jung; Matija Snuderl; Alona Muzikansky; Kay G Stubenrauch; Oliver Krieter; Hiroaki Wakimoto; Lei Xu; Lance L Munn; Dan G Duda; Dai Fukumura; Tracy T Batchelor; Rakesh K Jain
Journal:  Proc Natl Acad Sci U S A       Date:  2016-04-04       Impact factor: 11.205

6.  Treg Depletion Licenses T Cell-Driven HEV Neogenesis and Promotes Tumor Destruction.

Authors:  Emily J Colbeck; Emma Jones; James P Hindley; Kathryn Smart; Ralph Schulz; Molly Browne; Scott Cutting; Anwen Williams; Lee Parry; Andrew Godkin; Carl F Ware; Ann Ager; Awen Gallimore
Journal:  Cancer Immunol Res       Date:  2017-09-25       Impact factor: 11.151

7.  Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming.

Authors:  Lin Tian; Amit Goldstein; Hai Wang; Hin Ching Lo; Ik Sun Kim; Thomas Welte; Kuanwei Sheng; Lacey E Dobrolecki; Xiaomei Zhang; Nagireddy Putluri; Thuy L Phung; Sendurai A Mani; Fabio Stossi; Arun Sreekumar; Michael A Mancini; William K Decker; Chenghang Zong; Michael T Lewis; Xiang H-F Zhang
Journal:  Nature       Date:  2017-04-03       Impact factor: 49.962

8.  Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade.

Authors:  Ziming Wang; Ethan G Aguilar; Jesus I Luna; Cordelia Dunai; Lam T Khuat; Catherine T Le; Annie Mirsoian; Christine M Minnar; Kevin M Stoffel; Ian R Sturgill; Steven K Grossenbacher; Sita S Withers; Robert B Rebhun; Dennis J Hartigan-O'Connor; Gema Méndez-Lagares; Alice F Tarantal; R Rivkah Isseroff; Thomas S Griffith; Kurt A Schalper; Alexander Merleev; Asim Saha; Emanual Maverakis; Karen Kelly; Raid Aljumaily; Sami Ibrahimi; Sarbajit Mukherjee; Michael Machiorlatti; Sara K Vesely; Dan L Longo; Bruce R Blazar; Robert J Canter; William J Murphy; Arta M Monjazeb
Journal:  Nat Med       Date:  2018-11-12       Impact factor: 53.440

9.  Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy.

Authors:  Hong Jiang; Samarth Hegde; Brett L Knolhoff; Yu Zhu; John M Herndon; Melissa A Meyer; Timothy M Nywening; William G Hawkins; Irina M Shapiro; David T Weaver; Jonathan A Pachter; Andrea Wang-Gillam; David G DeNardo
Journal:  Nat Med       Date:  2016-07-04       Impact factor: 53.440

Review 10.  Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy.

Authors:  Matthias Pinter; Rakesh K Jain
Journal:  Sci Transl Med       Date:  2017-10-04       Impact factor: 17.956
View more
  42 in total

Review 1.  Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges.

Authors:  John D Martin; Horacio Cabral; Triantafyllos Stylianopoulos; Rakesh K Jain
Journal:  Nat Rev Clin Oncol       Date:  2020-02-07       Impact factor: 66.675

Review 2.  Physical traits of cancer.

Authors:  Hadi T Nia; Lance L Munn; Rakesh K Jain
Journal:  Science       Date:  2020-10-30       Impact factor: 47.728

3.  A pan-cancer analysis of the human tumor coagulome and its link to the tumor immune microenvironment.

Authors:  Zuzana Saidak; Simon Soudet; Marine Lottin; Valéry Salle; Marie-Antoinette Sevestre; Florian Clatot; Antoine Galmiche
Journal:  Cancer Immunol Immunother       Date:  2020-10-15       Impact factor: 6.968

Review 4.  The Interplay of the Extracellular Matrix and Stromal Cells as a Drug Target in Stroma-Rich Cancers.

Authors:  Nina Kozlova; Joseph E Grossman; Marcin P Iwanicki; Taru Muranen
Journal:  Trends Pharmacol Sci       Date:  2020-01-31       Impact factor: 14.819

5.  Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models.

Authors:  Amaia Martinez-Usatorre; Ece Kadioglu; Gael Boivin; Chiara Cianciaruso; Alan Guichard; Bruno Torchia; Nadine Zangger; Sina Nassiri; Ioanna Keklikoglou; Martina Schmittnaegel; Carola H Ries; Etienne Meylan; Michele De Palma
Journal:  Sci Transl Med       Date:  2021-08-11       Impact factor: 17.956

6.  Dual role of endothelial Myct1 in tumor angiogenesis and tumor immunity.

Authors:  Ashraf Ul Kabir; Madhav Subramanian; Dong Hun Lee; Xiaoli Wang; Karen Krchma; Jun Wu; Teri Naismith; Carmen M Halabi; Ju Young Kim; Fadi E Pulous; Brian G Petrich; Suhyun Kim; Hae-Chul Park; Phyllis I Hanson; Hua Pan; Samuel A Wickline; Daved H Fremont; Changwon Park; Kyunghee Choi
Journal:  Sci Transl Med       Date:  2021-03-03       Impact factor: 17.956

Review 7.  Mechanisms of primary and acquired resistance to PD-1/PD-L1 blockade and the emerging role of gut microbiome.

Authors:  R Zou; Y Wang; S Cui; F Ye; X Zhang; M Wang
Journal:  Clin Transl Oncol       Date:  2021-05-17       Impact factor: 3.405

8.  DLL1 orchestrates CD8+ T cells to induce long-term vascular normalization and tumor regression.

Authors:  Naidong Zhang; Rongping Yin; Pei Zhou; Xiaomei Liu; Peng Fan; Long Qian; Li Dong; Chenglin Zhang; Xichen Zheng; Shengming Deng; Jiajie Kuai; Zhenhua Liu; Wen Jiang; Xiaohua Wang; Depei Wu; Yuhui Huang
Journal:  Proc Natl Acad Sci U S A       Date:  2021-06-01       Impact factor: 11.205

9.  Compressed vessels bias red blood cell partitioning at bifurcations in a hematocrit-dependent manner: Implications in tumor blood flow.

Authors:  Romain Enjalbert; David Hardman; Timm Krüger; Miguel O Bernabeu
Journal:  Proc Natl Acad Sci U S A       Date:  2021-06-17       Impact factor: 11.205

Review 10.  Overcoming physical stromal barriers to cancer immunotherapy.

Authors:  Seung Woo Chung; Yunxuan Xie; Jung Soo Suk
Journal:  Drug Deliv Transl Res       Date:  2021-08-05       Impact factor: 4.617
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.